DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice

Gaku Matsumoto1, Mohammad Atiqur Rahman, Mariko Muta

  • 1Department of Surgery, Tokyo Metropolitan Komagome Hospital, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. gaku0508@ruby.ocn.ne.jp

Oncology Reports
|July 16, 2004
PubMed

Insights

DFU demonstrated anti-cancer effects by inhibiting tumor growth, apoptosis, and angiogenesis in mice. These inhibitory effects appear to be dependent on Cyclooxygenase-2 (COX-2) expression.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) inhibitors show promise in cancer treatment.
  • The anti-cancer mechanisms of these drugs remain largely unknown.

Purpose of the Study:

  • To investigate the anti-cancer effects of DFU (a COX-2 inhibitor).
  • To explore the in vitro and in vivo mechanisms of DFU on MCF-7 breast cancer cells and tumors.

Main Methods:

  • In vitro studies on MCF-7 cell growth.
  • In vivo studies using MCF-7 tumor xenografts in mice.
  • Immunostaining to assess apoptosis, angiogenesis, and COX-2 expression in tumor tissues.

Main Results:

  • DFU inhibited tumor growth in mice compared to controls.
  • Apoptosis was observed in DFU-treated tumors.
  • DFU treatment decreased angiogenesis and reduced COX-2 expression.
  • DFU exhibited growth inhibitory effects on MCF-7 cells in vitro.

Conclusions:

  • DFU possesses significant anti-cancer properties.
  • The anti-cancer effects of DFU are likely mediated through COX-2 inhibition.
  • DFU may represent a potential therapeutic agent for cancer treatment.

Related Concept Videos